阻断疗法-话题@MedSci

#阻断疗法#

12篇内容 | 338人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1816454, encodeId=4015181645475, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=Prostate Cancer P D：雄性激素阻断疗法和认知能力下降与大脑连接体、内分泌状况和风险基因型的关联情况 , objectType=article, longId=213228, objectId=ab832132287d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab832132287d, replyNumber=0, likeNumber=0, createdTime=2022-03-16, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab832132287d, moduleTitle=Prostate Cancer P D：雄性激素阻断疗法和认知能力下降与大脑连接体、内分泌状况和风险基因型的关联情况 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab832132287d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816453, encodeId=16d21816453c9, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=Eur Urol Oncol：雄激素阻断疗法与多西他赛联用治疗高风险生化复发前列腺癌, objectType=article, longId=212395, objectId=fb5e21239575, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb5e21239575, replyNumber=0, likeNumber=40, createdTime=2022-01-15, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb5e21239575, moduleTitle=Eur Urol Oncol：雄激素阻断疗法与多西他赛联用治疗高风险生化复发前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb5e21239575)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816455, encodeId=842c1816455d5, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=《细胞》子刊：内外夹击，效果更强！科学家揭示PD-1和TIGIT共同阻断疗法的抗癌机制，共同为CD226解围来激活T细胞抗癌功能, objectType=article, longId=302024, objectId=76f13020240e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76f13020240e, replyNumber=0, likeNumber=43, createdTime=2022-10-20, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76f13020240e, moduleTitle=《细胞》子刊：内外夹击，效果更强！科学家揭示PD-1和TIGIT共同阻断疗法的抗癌机制，共同为CD226解围来激活T细胞抗癌功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76f13020240e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816451, encodeId=89ec1816451aa, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=Eur Urol：致病性生殖系DNA损伤修复变异对新辅助激素阻断疗法响应的影响, objectType=article, longId=211368, objectId=35b521136835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35b521136835, replyNumber=0, likeNumber=41, createdTime=2021-07-13, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35b521136835, moduleTitle=Eur Urol：致病性生殖系DNA损伤修复变异对新辅助激素阻断疗法响应的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35b521136835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816450, encodeId=44071816450d9, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=JAMA Netw Open：恩扎鲁胺与比卡鲁胺联合雄激素阻断疗法对转移激素敏感型前列腺癌男性的临床疗效 , objectType=article, longId=206888, objectId=c9c720688846, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9c720688846, replyNumber=0, likeNumber=51, createdTime=2021-04-10, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9c720688846, moduleTitle=JAMA Netw Open：恩扎鲁胺与比卡鲁胺联合雄激素阻断疗法对转移激素敏感型前列腺癌男性的临床疗效 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9c720688846)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816449, encodeId=63f91816449cc, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=Cancer：前列腺癌患者接受雄激素阻断疗法的系统性炎症和症状学, objectType=article, longId=205536, objectId=0ec52055360c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec52055360c, replyNumber=0, likeNumber=37, createdTime=2021-10-17, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec52055360c, moduleTitle=Cancer：前列腺癌患者接受雄激素阻断疗法的系统性炎症和症状学, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ec52055360c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816447, encodeId=b968181644eb7, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=Nat Immun：PD-1阻断疗法有用吗？日本科学家提出一种新的疗效指标, objectType=article, longId=200668, objectId=3b24200668d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b24200668d8, replyNumber=0, likeNumber=38, createdTime=2020-11-16, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b24200668d8, moduleTitle=Nat Immun：PD-1阻断疗法有用吗？日本科学家提出一种新的疗效指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b24200668d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816448, encodeId=1e6c1816448e9, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法, objectType=article, longId=202749, objectId=c7e3202e494d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7e3202e494d, replyNumber=0, likeNumber=36, createdTime=2021-02-28, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7e3202e494d, moduleTitle=Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7e3202e494d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816452, encodeId=a55e18164521f, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=Eur Urol：异时性转移激素敏感性前列腺癌男性中恩杂鲁胺和雄激素阻断疗法治疗的总生存率研究 , objectType=article, longId=212266, objectId=dc142122664a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc142122664a, replyNumber=0, likeNumber=37, createdTime=2021-12-26, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc142122664a, moduleTitle=Eur Urol：异时性转移激素敏感性前列腺癌男性中恩杂鲁胺和雄激素阻断疗法治疗的总生存率研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc142122664a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816446, encodeId=57eb1816446f7, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=Nature Cancer：PAK4抑制可促进PD-1免疫阻断疗法, objectType=article, longId=184886, objectId=9ae51848866e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ae51848866e, replyNumber=0, likeNumber=51, createdTime=2020-04-15, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ae51848866e, moduleTitle=Nature Cancer：PAK4抑制可促进PD-1免疫阻断疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ae51848866e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816444, encodeId=bf4e1816444cb, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=Lancet：同卵双胎中雄激素阻断疗法引起的性腺机能减退——案例报道, objectType=article, longId=72413, objectId=a12ae241318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a12ae241318, replyNumber=0, likeNumber=36, createdTime=2017-02-11, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a12ae241318, moduleTitle=Lancet：同卵双胎中雄激素阻断疗法引起的性腺机能减退——案例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a12ae241318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816445, encodeId=b25a18164457b, content=<a href='/topic/show?id=438d9e6860b' target=_blank style='color:#2F92EE;'>#阻断疗法#</a>, objectTitle=2016循证建议——雄激素阻断疗法治疗局限性和晚期前列腺癌发布, objectType=article, longId=75910, objectId=d3dbe5910fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3dbe5910fe, replyNumber=0, likeNumber=44, createdTime=2016-11-24, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3dbe5910fe, moduleTitle=2016循证建议——雄激素阻断疗法治疗局限性和晚期前列腺癌发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3dbe5910fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阻断疗法

2020-05-29

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#阻断疗法#

Prostate Cancer P D：雄性激素阻断疗法和认知能力下降与大脑连接体、内分泌状况和风险基因型的关联情况

2022-03-16

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#阻断疗法#

Eur Urol Oncol：雄激素阻断疗法与多西他赛联用治疗高风险生化复发前列腺癌

2022-01-15

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#阻断疗法#

《细胞》子刊：内外夹击，效果更强！科学家揭示PD-1和TIGIT共同阻断疗法的抗癌机制，共同为CD226解围来激活T细胞抗癌功能

2022-10-20

医者仁心 (审核中...)

前往app查看评论内容

#阻断疗法#

Eur Urol：致病性生殖系DNA损伤修复变异对新辅助激素阻断疗法响应的影响

2021-07-13

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#阻断疗法#

JAMA Netw Open：恩扎鲁胺与比卡鲁胺联合雄激素阻断疗法对转移激素敏感型前列腺癌男性的临床疗效

2021-04-10

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#阻断疗法#

Cancer：前列腺癌患者接受雄激素阻断疗法的系统性炎症和症状学

2021-10-17

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#阻断疗法#

Nat Immun：PD-1阻断疗法有用吗？日本科学家提出一种新的疗效指标

2020-11-16

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#阻断疗法#

Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法

2021-02-28

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#阻断疗法#

Eur Urol：异时性转移激素敏感性前列腺癌男性中恩杂鲁胺和雄激素阻断疗法治疗的总生存率研究

2021-12-26

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#阻断疗法#

Nature Cancer：PAK4抑制可促进PD-1免疫阻断疗法

2020-04-15

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#阻断疗法#

Lancet：同卵双胎中雄激素阻断疗法引起的性腺机能减退——案例报道

2017-02-11

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#阻断疗法#

2016循证建议——雄激素阻断疗法治疗局限性和晚期前列腺癌发布

2016-11-24

科室
- - 订阅+
  - 更多科室
工具
服务